HC Wainwright Predicts BioNTech FY2024 Earnings

BioNTech SE (NASDAQ:BNTX) – HC Wainwright issued their FY2024 earnings estimates for shares of BioNTech in a research report issued to clients and investors on Monday, March 10th. HC Wainwright analyst R. Burns expects that the company will earn ($5.24) per share for the year. HC Wainwright has a “Buy” rating and a $150.00 price objective on the stock. The consensus estimate for BioNTech’s current full-year earnings is ($3.88) per share. HC Wainwright also issued estimates for BioNTech’s Q4 2024 earnings at $0.06 EPS, Q1 2025 earnings at ($3.42) EPS, Q2 2025 earnings at ($3.50) EPS, Q3 2025 earnings at $0.26 EPS, Q4 2025 earnings at $0.19 EPS and FY2025 earnings at ($6.43) EPS.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.70. The company had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.24 billion. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm’s revenue was down 19.5% compared to the same quarter last year. During the same period in the prior year, the company earned $1.90 earnings per share.

BNTX has been the topic of a number of other reports. Truist Financial started coverage on shares of BioNTech in a report on Friday, January 10th. They set a “buy” rating and a $172.00 target price on the stock. Morgan Stanley dropped their target price on shares of BioNTech from $145.00 to $139.00 and set an “overweight” rating on the stock in a report on Tuesday. JPMorgan Chase & Co. cut their price objective on shares of BioNTech from $124.00 to $122.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 26th. Berenberg Bank started coverage on shares of BioNTech in a research report on Tuesday, November 19th. They issued a “buy” rating and a $130.00 price objective on the stock. Finally, BMO Capital Markets lifted their price objective on shares of BioNTech from $130.00 to $143.00 and gave the company an “outperform” rating in a research report on Tuesday. Three equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, BioNTech currently has a consensus rating of “Moderate Buy” and an average price target of $143.65.

BioNTech Stock Down 6.6 %

Shares of NASDAQ:BNTX opened at $98.39 on Wednesday. The stock has a market capitalization of $23.59 billion, a price-to-earnings ratio of -46.85 and a beta of 0.30. BioNTech has a 1-year low of $76.53 and a 1-year high of $131.49. The company’s fifty day moving average is $116.45 and its two-hundred day moving average is $113.13. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33.

Institutional Trading of BioNTech

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Planning Capital Management Corp grew its stake in shares of BioNTech by 45,000.0% in the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock worth $54,000 after purchasing an additional 450 shares during the last quarter. Jones Financial Companies Lllp grew its stake in shares of BioNTech by 110.3% in the 4th quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock worth $53,000 after purchasing an additional 246 shares during the last quarter. Quintet Private Bank Europe S.A. grew its stake in shares of BioNTech by 823.5% in the 4th quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company’s stock worth $88,000 after purchasing an additional 700 shares during the last quarter. Allianz SE acquired a new position in shares of BioNTech in the 4th quarter worth approximately $90,000. Finally, GAMMA Investing LLC grew its stake in shares of BioNTech by 48.2% in the 4th quarter. GAMMA Investing LLC now owns 923 shares of the company’s stock worth $105,000 after purchasing an additional 300 shares during the last quarter. 15.52% of the stock is currently owned by institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.